Overview
Accuray fiscal Q1 2026 rev down 7% yr/yr, but beats analysts' expectations
Net loss widens significantly from prior year
Company initiated restructuring plan, incurring $2.8 mln in charges
Outlook
Accuray reaffirms fiscal 2026 revenue guidance of $471 mln to $485 mln
Accuray expects fiscal 2026 adjusted EBITDA of $31 mln to $35 mln
Company focuses on strategic transformation and restructuring for future growth
Result Drivers
RESTRUCTURING PLAN - Co initiated restructuring to reduce costs and streamline operations, incurring $2.8 mln in charges
SERVICE REVENUE INCREASE - Service revenue grew 7% yr/yr, offsetting decline in product revenue
PRODUCT INTRODUCTION - Introduction of Accuray Stellar Solution in U.S. market seen as growth opportunity
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $93.94 mln | $92.20 mln (3 Analysts) |
Q1 Net Income | -$21.68 mln | ||
Q1 Basic EPS | -$0.18 | ||
Q1 Gross Profit | $26.55 mln | ||
Q1 Income From Operations | -$11.31 mln | ||
Q1 Operating Expenses | $37.86 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Accuray Inc is $4.75, about 70.9% above its November 4 closing price of $1.38
Press Release: ID:nPn2SsZNga
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)